A single-dose, 3-way, 3-period, 6-sequence, crossover study to evaluate the bioequivalence of Emtricitabine/Rilpivirine/Tenofovir-alafenamide as a single tablet regimen versus Cobicistat/Elvitegravir/Emtricitabine/Tenofovir-alafenamide and Rilpivirine in healthy volunteers

Trial Profile

A single-dose, 3-way, 3-period, 6-sequence, crossover study to evaluate the bioequivalence of Emtricitabine/Rilpivirine/Tenofovir-alafenamide as a single tablet regimen versus Cobicistat/Elvitegravir/Emtricitabine/Tenofovir-alafenamide and Rilpivirine in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2016

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top